The future of antifungal therapy

Clinical Infectious Diseases

Volumn 22, Issue SUPPL. 2, 1996, Pages

  Graybill, John R ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE INHIBITOR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN B; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NIKKOMYCIN; NIKKOMYCIN Z; PENTAMIDINE; PRADIMICIN A; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FUNGICIDAL ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOKALEMIA; IMMUNOMODULATION; MOLECULAR BIOLOGY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL;

EID: 0030017445     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.supplement_2.s166     Document Type: Conference Paper

References (147)

1. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis, and treatment, and review of the literature. Medicine (Baltimore) 1990;69:361-74.
2. Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection: a review of 77 patients. Medicine (Baltimore) 1990;69:384-91.
3. Jones JL, Fleming PL, Ciesielski CA, Hu DJ, Kaplan JE, Ward JW. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995;171:961-6.
4. Deng Z, Ribas JL, Gibson DW, Connor DH. Infections caused by Penicillium marneffei in China and Southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev Infect Dis 1988;10:640-52.
5. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994;344:110-3.
6. Einstein H. The coccidioidomycosis epidemic of 1991-1993 [abstract PO1.113]. In: Program and abstracts of the 12th Congress of the International Society for Human and Animal Mycology (Adelaide, South Australia). Adelaide: International Society for Human and Animal Mycology, 1994.
7. Stevens DA. Coccidioidomycosis. New Engl J Med 1995;332:1077-82.
8. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837-42.
9. Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610-6.
10. Norris S, Wheat J, McKinsey D, et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med 1994;96:504-8.
11. McKinsey DS, Gupta MR, Riddler SA, Driks MR, Smith DL, Kurtin PJ. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;111:655-9.
12. Wheat L, Mawhinney S, Hafner R, McKinsey D. Fluconazole treatment for histoplasmosis in AIDS: prospective multicenter non-comparative trial [abstract 1233]. In: Program and abstracts of the 34th Interscience Conference of Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
13. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New Engl J Med 1992;326:83-9.
14. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole. Ann Intern Med 1985;103:861-72.
15. Johnson PC, Khardori N, Najjar AF, Butt F, Mansell PWA, Sarosi GA. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:152-8.
16. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995;98:336-42.
17. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New Engl J Med 1991;325:1274-7.
18. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
19. Wingard JR. Importance of Candida species other than C. abicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.
20. Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988;67: 77-83.
21. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-74.
22. Bailey EM, Krakovsky DJ, Rybak MJ. The triazole antifungal agents: a review of itraconazole and fluconazole. Pharmacotherapy 1990;10: 146-53.
23. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. New Engl J Med 1994;330:263-72.
24. Redding S, Smith J, Farinacci G, et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 1994;18:240-2.
25. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
26. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New Engl J Med 1992;326:845-51.
27. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
28. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
29. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD, Zervos MJ. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis 1993;168:195-201.
30. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis of intraabdominal candidiasis in high-risk surgical patients: a double-blind, placebo-controlled study [abstract M79]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
31. Pirsch JD, Maki DG. Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow: increased susceptibility to fungal infections. Ann Intern Med 1986;104:619-31.
32. Morrison VA, Haake RJ, Weisdorf DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994;96:497-503.
33. Hagensee ME, Bauwens JE, Kjos B, Bowden RA. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994;19:402-8.
34. de Marie S, Janknegt R, Bakker-Woudenberg IAJM. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994;33:907-16.
35. Meunier F, Prentice HG, Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991;28(suppl B):83-91.
36. Collette N, van der Auwera P, Meunier F, Lambert C, Sculier JP, Coune A. Tissue distribution and bioactivity of amphotericin B administered in liposomes to cancer patients. J Antimicrob Chemother 1991;27: 535-48.
37. Schmitt H-J. New methods of delivery of amphotericin B. Clin Infect Dis 1993;17(suppl 2):S501-6.
38. Janknegt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA. Liposomal and lipid formulations of amphotericin B: clinical pharmacokinetics. Clin Pharmacokinet 1992;23:279-91.
39. Ringdén O, Andstrōm E, Remberger M, Svahn BM, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant 1994;14(suppl 5):S10-4.
40. Walsh TJ, Hiemenz JW, Seibel N, Anaissie EJ. Amphotericin B lipid complex in the treatment of 228 cases of invasive mycosis [abstract M69]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
41. Arning M, Heer-Sonderhoff AH, Wehmeier A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia. Eur J Clin Microbiol Infect Dis 1995;14:41-3.
42. Viviani MA, Rizzardini G, Tortorano AM, et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 1994;22:137-42.
43. Coker R, Tomlinson D, Harris J. Successful treatment of cryptococcal meningitis with liposomal amphotericin B after failure of treatment with fluconazole and conventional amphotericin B [letter]. AIDS 1991;5:231-2.
44. Begue RE, Lindo-Soriano I. Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis [letter]. J Infect Dis 1991;164:620.
45. Graybill JR, Sharkey PK, Vincent D, et al. Amphotericin B lipid complex (ABLC) in treatment (Rx) of cryptococcal meningitis (CM) in patients with AIDS [abstract 289]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1991.
46. Thaler M, Pastakia B, Shawker TH, O'Leary T, Pizzo PA. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988;108:88-100.
47. Gonzalez C, Lyman C, Lee S, et al. Limited site-dependent antifungal activity of amphotericin B (AmB) in experimental disseminated fusariosis in neutropenic hosts [abstract B2]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
48. Anaissie EJ, Ramphal R. Efficacy and safety of amphotericin B lipid complex (ABLC) in the treatment of patients with life-threatening fusariosis [abstract M87]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
49. Denning DW, Lee JY, Hosteller JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
50. Loebenberg D, Cacciapuoti A, Parmegiani R, et al. In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304. Antimicrob Agents Chemother 1992;36:498-501.
51. Patterson TF, George D, Ingersoll R, Miniter P, Andriole VT. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother 1991;35:1985-8.
52. Hosteller JS, Catanzaro A, Stevens DA, et al. Treatment of coccidioidomycosis with SCH 39304. J Med Vet Mycol 1994;32:105-14.
53. Anaissie EJ, Kontoyiannis DP, Vartivarian S, et al. Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis 1993;17:1022-31.
54. Franco L, Gomez I, Restrepo A. Saperconazole in the treatment of systemic and subcutaneous mycoses. Int J Dermatol 1992;31:725-9.
55. van Cutsem J, van Gerven F, Janssen PAJ. Saperconazole, a new potent antifungal triazole: in vitro activity spectrum and therapeutic efficacy. Drugs of the Future 14:1187-209.
56. Smith J, Hardin TC, Patterson TF, Rinaldi MG, Graybill JR. Rifabutin (Rif) decreases itraconazole (ITRA) plasma levels in patients with HIV-infection [abstract 126]. In: Abstracts and program of the 2nd National Conference on Human Retroviruses and Related Infections. Washington, DC, 1995.
57. Hosteller JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal azoles. Antimicrob Agents Chemother 1992;36:477-80.
58. Prentice AG, Warnock DW, Johnson SAN, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994;34:247-52.
59. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32: 1310-3.
60. Graybill JR, Vazquez J, Darouiche RO, Morhart R, Moskovitz BL, Mallegol I. Itraconazole oral solution (IS) versus fluconazole (F) treatment of oropharyngeal candidiasis (OC) [abstract I220]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
61. Persat F, Marzullo C, Guyotat D, Rochet M-J, Piens M-A. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992;28A:838-41.
62. Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
63. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-201.
64. Bowden RA, Cays M. Phase I study of amphotericin B colloidal dispersion (ABCD) for the treatment of invasive fungal infection after marrow transplant [abstract 56]. Trends in Invasive Fungal Infections II (Manchester, UK). 1993.
65. Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754-60.
66. Ringdén O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991;28(suppl B):73-82.
67. Garnis AS, Gudnason T, Giebink GS, Ramsay NKC. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev Infect Dis 1991;13:1077-88.
68. Merz WG, Karp JE, Hoagland M, Jett-Goheen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis 1988;158:1046-55.
69. McWhinney PHM, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397-404.
70. Caillot D, Durand C, Casasnovas RO, et al. Interest of CT-scan in emergency surgical management of invasive pulmonary aspergillosis (IPA) [abstract J110]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
71. Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993;37:1962-5.
72. Vanden Bossche H, Warnock DW, Dupont B, et al. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol 1994;32(suppl 1):189-202.
73. Parkinson T, Falconer DJ, Hitchcock CA. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob Agents Chemother 1995;39:1696-9.
74. Ghannoum MA, Spellberg BJ, Ibrahim AS, et al. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother 1994;38:2029-33.
75. Filler SG, Hobbs C, Ibrahim AS, Edwards JE Jr, Ghannoum MA. Candida krusei contains novel membrane sterols [abstract C35]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
76. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:1530-3.
77. Barchiesi F, Colombo AL, McGough DA, Fothergill AW, Rinaldi MG. In vitro activity of a new antifungal triazole, D0870, against Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38: 2553-6.
78. Karyotakis NC, Dignani MC, Hachem R, Anaissie EJ. Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections. Antimicrob Agents Chemother 1995;39:571-3.
79. Yamada H, Tsuda T, Watanabe T, Ohashi M, Murakami K, Mochizuki H. In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrob Agents Chemother 1993;37:2412-7.
80. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39: 314-9.
81. de Wit S, Dupont B, Cartledge JD, et al. Pilot study of a new triazole derivative (D0870) in HIV patients with oral candidiasis (OPC) [abstract 1225]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
82. Cartledge JD, Denning D, Dupont B, et al. Treatment of fluconazole (FCZ) resistant (res) oral candidosis (OC) with D0870 in patients with AIDS (PWA) [abstract M89]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
83. Denning DW, Hall L, Jackson M, Hollis S. Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis. Antimicrob Agents Chemother 1995;39: 1809-14.
84. Colombo AL, Holmberg JD, McGough DA, Rinaldi MG. In vitro activity of SCH 51048 against 70 clinical isolates of Aspergillus spp. [abstract F179]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
85. Allendoerfer R, Loebenberg D, Rinaldi MG, Graybill JR. Evaluation of SCH 51048 in an experimental model of pulmonary aspergillosis [abstract F189]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
86. Karyotakis NC, Hachem R, Anaissie EJ. Comparison of the efficacy of SCH 51048, fluconazole and amphotericin B against disseminated Trichosporon beigelii infection in immunosuppressed mice [abstract F195]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
87. Nomeir AA, Kim HK, Loebenberg D, Hare R, Miller GH, Lin CC. Comparative pharmacokinetics of a new triazole antifungal agent, SCH 51048, in mice, rats, rabbits, dogs, and cynomolgus monkeys [abstract F197]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
88. Cacciapuoti A, Parmegiani R, Loebenberg D, et al. Efficacy of SCH 56592 in pulmonary aspergillosis and candidiasis in mice [abstract F66]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
89. Galgiani JN, Lewis ML, Peng T. In vitro studies of a new azole antifungal drug, SCH 56592 [abstract F63]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
90. Barchiesi F, Restrepo M, McGough DA, Rinaldi MG. In vitro activity of a new antifungal triazole: UK-109,496 [abstract F71]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
91. Troke PF, Brammer KW, Hitchcock CA, Yonren S, Sarantis N. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC) [abstract F73]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
92. Hitchcock CA, Andrews RJ, Lewis BGH, Troke PF. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus [abstract F74] In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
93. Hajjeh RA, Blumberg HM. Bloodstream infection due to Trichosporon beigelii in a bum patient: case report and review of therapy. Clin Infect Dis 1995;20:913-6.
94. Anaissie E, Gokaslan A, Hachem R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992;15:781-7.
95. Bartizal K, Abruzzo G, Krupa TD, et al. In vitro antifungal activities and in vivo efficacies of 1,3-β-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulocandin. Antimicrob Agents Chemother 1992;36:1648-57.
96. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of water-soluble pneumocandin analogs L-733560, L-70589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1995;39:1077-81.
97. Bartizal K, Scott T, Abruzzo GK, et al. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother 1995;39: 1070-6.
98. Kurtz MB, Douglas C, Marrinan J, et al. Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother 1994;38:2750-7.
99. Raab P, Zeckner D, Boyll B, Boylan C, Current W. LY303366: comparison of activity in murine models of Aspergillus fumigatus infection [abstract F167]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
100. Zeckner D, Butler T, Boylan C, Boyll B, Raab P, Current W. LY303366: activity in a rat mucocutaneous vaginal candidiasis model [abstract F169]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
101. Green L, Petersen B, Raab P, Zeckner D, Current WL, Radding JA. Cryptococcus neoformans from host animals exhibits decreased susceptibility to aureobasidin A (R106-1, LY295337) [abstract F165]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
102. Chapman T, Kinsman O, Houston J. Chitin biosynthesis in Candida albicans grown in vitro and in vivo and its inhibition by nikkomycin Z. Antimicrob Agents Chemother 1992;36:1909-14.
103. Hector RF, Schaller K. Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1992;36:1284-9.
104. Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother 1995; 39:295-300.
105. Kakushima M, Masuyoshi S, Hirano M, et al. In vitro and in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative. Antimicrob Agents Chemother 1991;35:2185-90.
106. Allendoerfer R, Marquis AJ, Rinaldi MG, Graybill JR. Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 1991;35:726-9.
107. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5.
108. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113:183-7.
109. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New Engl J Med 1992;326:83-9.
110. Nguyen MH, Barchiesi F, McGough DA, Yu VL, Rinaldi MG. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995;39:1691-5.
111. Najvar L, Bocanegra R, Luther M, Graybill J. Treatment of murine disseminated candidiasis (Cds) with C. tropicalis (CT) using fluconazole (F) and a new triazole, D0870 (D) [abstract F201]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
112. Najvar L, Holmberg J, Luther M, Graybill JR. Fluconazole (F) and D0870 (D) treatment of murine candidiasis with C. albicans (CA) resistant in vitro to fluconazole [abstract F96]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
113. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985;151:902-10.
114. Albert MM, Graybill JR, Rinaldi MG. Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination. Antimicrob Agents Chemother 1991;35:1721-5.
115. Sugar AM. Interactions of amphotericin B and SCH 39304 in the treatment of experimental murine candidiasis: lack of antagonism of polyene-azole combination. Antimicrob Agents Chemother 1991;35: 1669-71.
116. Sugar AM, Salibian M, Goldani LZ. Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B. Antimicrob Agents Chemother 1994;38:371-3.
117. Sugar AM, Hitchcock CA, Troke PF, Picard M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995;39:598-601.
118. Vitt CR, Fidler JM, Ando D, Zimmerman RJ, Aukerman SL. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat. J Infect Dis 1994;169:369-74.
119. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocytemacrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993;17:705-7.
120. Dignani MC, Anaissie EJ, Hester JP, et al. A phase I/II study of granulocyte-colony stimulating factor (G-CSF) elicited white blood cell transfusions (WBCTx) for neutropenia-related fungal infections [abstract G54]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
121. Hennequin C, Benkerrou M, Gaillard JL, Blanche S, Fraitag S. Role of granulocyte colony-stimulating factor in the management of infection with Fusarium oxysponim in a neutropenic child [letter]. Clin Infect Dis 1994;18:490-1.
122. Grauer ME, Bokemeyer C, Bautsch W, Freund M, Link H. Successful treatment of a Trichosporon beigelii septicemia in a granulocytopenic patient with amphotericin B and granulocyte colony-stimulating factor. Infection 1994;22:283-6.
123. Bushelman SJ, Callen JP, Roth DN, Cohen LM. Disseminated Fusarium solani infection. J Am Acad Dermatol 1995;32:346-51.
124. Strauss RG. Granulocyte transfusion therapy. Hematol Oncol Clin North Am 1994;8:1159-66.
125. Kojima S, Matsuyama T. Stimulation of granulopoiesis by high-dose recombinant human granulocyte colony-stimulating factor in children with aplastic anemia and very severe neutropenia. Blood 1994;83: 1474-8.
126. Polak-Wyss A. Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice. Mycoses 1991;34:109-18.
127. Graybill JR, Bocanegra R, Albert M, Najvar L, Lambros C. Therapy of murine candidiasis with combination granulocyte colony stimulating factor (GCSF) and fluconazole (FLU) [abstract P4.6]. In: Program and abstracts of the 12th Congress of the International Society for Human and Animal Mycology (Adelaide, South Australia). Adelaide: International Society for Human and Animal Mycology, 1994.
128. Graybill J, Bocanegra R, Luther M. Treatment of murine cryptococcosis (Cr) with granulocyte colony stimulation factor (GCSF) and fluconazole (F) [abstract B18]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
129. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994;38:460-4.
130. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon-γ in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994;170:1331-4.
131. Louie A, Baltch AL, Smith RP, et al. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis. J Infect Dis 1995;171:406-15.
132. Subramanyam JM, Chung CL, Lavigne LM, Erickson JE, Hunter Mayor SE, Sypek JP. Effect of recombinant murine interleukin 12 (rmIL-12) in a murine model of Candida albicans infection [abstract B12]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
133. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-8.
134. van der Horst C, Saag M, Cloud G, et al. Randomized double blind comparison of amphotericin B plus flucytosine (AMB + FC) to AMB alone (STEP 1) followed by a comparison of fluconazole to itraconazole (STEP 2) in the treatment of acute cryptococcal meningitis in patients with AIDS [abstract 1216]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
135. Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome. Am J Med 1991;91:267-72.
136. Casadevall A, Mukherjee J, Devi SJN, Schneerson R, Robbins JB, Scharff MD. Antibodies elicited by a Cryptococcus neoformans tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 1992;165:1086-93.
137. Mukherjee J, Zuckier LS, Scharff MD, Casadevall A. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother 1994;38:580-7.
138. Zebedee SL, Koduri RK, Mukherjee J, et al. Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother 1994;38:1507-14.
139. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992;165:891-7.
140. Riley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509-14.
141. Tollemar J, Ringdén O, Anderson S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993;25: 1495-7.
142. Tollemar J, Höckerstedt K, Ericzon B-G, Jalanko H, Ringdén O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients: a randomized, placebo-controlled study. Transplantation 1995;59:45-50.
143. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
144. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. New Engl J Med 1995;332:700-5.
145. Currie BP, Casadevall A. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis 1994;19:1029-33.
146. Devi SJN, Schneerson R, Egan W, et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 1991;59:732-6.
147. Williamson PR, Bennett JE, Robbins J, Schneerson R. Vaccination for